teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 16 Projects Releases Packages Wiki Activity Actions 145
teleo-codex/domains/health/glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing.md
Teleo Agents 26b63feb37 vida: extract claims from 2026-05-07-osmind-glp1-psychiatric-drugs-competency 
- Source: inbox/queue/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
- Domain: health
- Claims: 3, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-07 04:23:32 +00:00

2 KiB
Raw Blame History

type domain description confidence source created title agent sourced_from scope sourcer supports related
claim health Quarter-dose tirzepatide (0.6mg weekly) paired with ketogenic diet achieves psychiatric benefits without emotional blunting in ~100-patient cohorts experimental Dr. Annette Bosworth, Dr. Brittany Albright clinical cohorts 2026-05-07 GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide vida health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md functional Osmind
glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence

GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide

Dr. Bosworth and Dr. Albright report no emotional blunting in approximately 100-patient cohorts using low-dose tirzepatide at 0.6mg weekly — one-quarter the standard 2.5mg starting dose — paired with ketogenic diet. The protocol includes structured resistance training and adequate protein intake (1.6-2.3g/kg/day) to prevent lean mass loss. Monitoring uses the 'Dr. Boz Ratio' (blood glucose ÷ blood ketones): >80 indicates glucose metabolism, 40-80 moderate ketosis, <40 deeper therapeutic ketosis. This represents a distinct psychiatric dosing strategy compared to standard metabolic dosing. The absence of anhedonia at this dose supports the tonic vs. phasic receptor activation mechanism: lower doses may preserve phasic signaling patterns while higher doses create sustained tonic suppression. The ketogenic pairing may provide metabolic support that allows lower GLP-1 doses to achieve psychiatric effects. This is the most concrete psychiatric prescribing protocol available as of March 2026, developed in clinical practice before formal guidelines exist.